Last Updated:
Searching
Create account to add to watchlist!

5:01 Acquisition Corp. - FVAM

  • Commons

    $9.87

    +0.20%

    FVAM Vol: 19.4K

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 85.4M
Average Volume: 12.3K
52W Range: $9.29 - $13.00
Weekly %: +0.41%
Monthly %: +0.71%
Inst Owners: 40

Info

Target: Searching
Days Since IPO: 414
Unit composition:
nan
Trust Size: 0.0M

Management

Officers and Directors Upon consummation of this offering, our board of directors will have five members, three of whom will be deemed “independent” under SEC and Nasdaq rules. Our board of directors will be divided into three classes with only one class of directors being elected in each year and each class serving a three-year term. The term of office of the first class of directors, consisting of Mr. Patterson will expire at our first annual meeting of stockholders. The term of office of the second class of directors, consisting of Ms. Beckman and Dr. Mackay, will expire at the second annual meeting. The term of office of the third class of directors, consisting of Mr. Schwab and Dr. Parmar, will expire at our third annual meeting of stockholders. We may not hold an annual meeting of stockholders until after we consummate our initial business combination. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws provide that our directors may consist of a chairman of the board, and that our officers may consist of co-chief executive officers, president, chief financial officer, executive vice president(s), vice president(s), secretary, treasurer and such other officers as may be determined by the board of directors. Director and Executive Compensation We have not paid any cash or equity compensation to our directors. Upon completion of this offering, we anticipate adopting a non-employee director compensation policy pursuant to which we will pay each non-employee director $50,000 annually, payable in equal monthly installments, for service on our board of directors. Our sponsor has also agreed to transfer 30,000 of its founder shares to each of Ms. Beckman, Dr. Mackay and Mr. Patterson when they join our board of directors upon the closing of this offering. No executive officer has received any cash compensation for services rendered to us. We do not currently anticipate that compensation of any kind (including finder’s fees, consulting fees or other similar 88 TABLE OF CONTENTS compensation) will be paid to our sponsor or either of our co-chief executive officers, for services rendered to us prior to or in connection with the consummation of our initial business combination (regardless of the type of transaction that it is). We may in the future enter into consulting or employment agreements with additional members of our management team, pursuant to which such persons may be entitled to cash or equity compensation. We have not yet entered into any such agreement and, accordingly, the compensatory terms for any such agreement have not yet been determined (other than the terms of our non-employee director compensation policy which we plan to adopt upon completion of this offering). Our sponsor, members of our management team and their affiliates will receive reimbursement for any out-of-pocket expenses incurred by them in connection with activities on our behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and business combinations as well as traveling to and from the offices, plants or similar locations of prospective target businesses to examine their operations. There is no limit on the amount of out-of-pocket expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available proceeds not deposited in the trust account and the interest income earned on the amounts held in the trust account, such expenses would not be reimbursed by us unless we consummate an initial business combination. After our initial business combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company with any and all amounts being fully disclosed to stockholders, to the extent then known, in the proxy solicitation materials furnished to our stockholders. It is unlikely the amount of such compensation will be known at the time of a stockholder meeting held to consider our initial business combination, as it will be up to the directors of the post-combination business to determine executive and director compensation. In this event, such compensation will be publicly disclosed at the time of its determination in a Current Report on Form 8-K, as required by the SEC. Director Independence Nasdaq listing standards require that within one year of the listing of our securities on The Nasdaq Capital Market we have at least three independent directors and that a majority of our board of directors be independent. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Our board of directors has determined that Ms. Beckman, Dr. Mackay and Mr. Patterson will qualify as “independent directors” as defined in the Nasdaq listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. We will only enter into a business combination if it is approved by a majority of our independent directors. Additionally, we will only enter into transactions with our officers and directors and their respective affiliates that are on terms no less favorable to us than could be obtained from independent parties. Any related-party transactions must be approved by our audit committee and a majority of our uninterested “independent directors,” or the disinterested directors who do not have an interest in the transaction. We will not enter into any such transaction unless our audit committee and a majority of our disinterested and independent directors determine that the terms of such transaction are no less favorable to us than those that would be available to us with respect to such a transaction from unaffiliated third parties. Audit Committee Effective as of the effective date of the registration statement of which this prospectus is a part, we will establish an audit committee of the board of directors, which will consist of Ms. Beckman, Dr. Mackay and Mr. Patterson, each of whom is an independent director. Ms. Beckman will serve as the chairperson of the audit committee. The audit committee’s duties, which are specified in our Audit Committee Charter, include, but are not limited to: • reviewing and discussing with management and the independent registered public accounting firm the annual audited financial statements, and recommending to the board whether the audited financial statements should be included in our Form 10-K; ​ 89 TABLE OF CONTENTS • discussing with management and the independent registered public accounting firm significant financial reporting issues and judgments made in connection with the preparation of our financial statements; ​ • discussing with management major risk assessment and risk management policies; ​ • monitoring the independence of the independent registered public accounting firm; ​ • verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; ​ • reviewing and approving all related-party transactions; ​ • inquiring and discussing with management our compliance with applicable laws and regulations; ​ • pre-approving all audit services and permitted non-audit services to be performed by our independent registered public accounting firm, including the fees and terms of the services to be performed; ​ • appointing or replacing the independent registered public accounting firm; ​ • determining the compensation and oversight of the work of the independent registered public accounting firm (including resolution of disagreements between management and the independent registered public accounting firm regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; ​ • establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; and ​ • approving reimbursement of expenses incurred by our management team in identifying potential target businesses. ​ Financial Experts on Audit Committee The audit committee will at all times be composed exclusively of “independent directors” who are “financially literate” as defined under the Nasdaq listing standards. The Nasdaq listing standards define “financially literate” as being able to read and understand fundamental financial statements, including a company’s balance sheet, income statement and cash flow statement. In addition, we must certify to Nasdaq that the committee has, and will continue to have, at least one member who has past employment experience in finance or accounting, requisite professional certification in accounting, or other comparable experience or background that results in the individual’s financial sophistication. The board of directors has determined that Ms. Beckman qualifies as an “audit committee financial expert,” as defined under rules and regulations of the SEC. Nominating Committee Effective as of the effective date of the registration statement of which this prospectus is a part, we will establish a nominating committee of the board of directors, which will consist of Ms. Beckman, Dr. Mackay and Mr. Patterson, each of whom is an independent director under Nasdaq’s listing standards. Dr. Mackay will serve as the chairperson of the nominating committee. The nominating committee is responsible for overseeing the selection of persons to be nominated to serve on our board of directors. The nominating committee considers persons identified by its members, management, stockholders, investment bankers and others. Guidelines for Selecting Director Nominees The guidelines for selecting nominees, which are specified in the Nominating Committee Charter, generally provide that persons to be nominated: 90 TABLE OF CONTENTS • should have demonstrated notable or significant achievements in business, education or public service; ​ • should possess the requisite intelligence, education and experience to make a significant contribution to the board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and ​ • should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the stockholders. ​ The nominating committee will consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism in evaluating a person’s candidacy for membership on the board of directors. The nominating committee may require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating committee does not distinguish among nominees recommended by stockholders and other persons. Compensation Committee Effective as of the effective date of the registration statement of which this prospectus is a part, we will establish a compensation committee of the board of directors consisting of Ms. Beckman, Dr. Mackay and Mr. Patterson, each of whom is an independent director. Mr. Patterson will serve as chairperson of the compensation committee. The compensation committee’s duties, which are specified in our Compensation Committee Charter, include, but are not limited to: • reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officers’ compensation, evaluating our Chief Executive Officers’ performance in light of such goals and objectives and determining and approving the remuneration (if any) of our Chief Executive Officers based on such evaluation; ​ • reviewing and approving the compensation of all of our other officers; ​ • reviewing our executive compensation policies and plans; ​ • implementing and administering our incentive compensation equity-based remuneration plans; ​ • assisting management in complying with our proxy statement and annual report disclosure requirements; ​ • approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees; ​ • producing a report on executive compensation to be included in our annual proxy statement; and ​ • reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. ​ The Compensation Committee Charter also provides that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC. Compensation Committee Interlocks and Insider Participation None of our directors who will serve as members of our compensation committee will be one of our officers or employees. None of our officers will serve as a member of the compensation committee of any other entity that has one or more officers serving on our board of directors. None of our officers will serve 91 TABLE OF CONTENTS as a member of the board of directors of any other entity that has one or more officers serving on our compensation committee. Code of Ethics Effective upon consummation of this offering, we will adopt a code of ethics that applies to all of our officers, directors and employees. The code of ethics codifies the business and ethical principles that govern all aspects of our business. A copy of the Code of Ethics will be provided without charge upon request from us. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report on Form 8-K. Conflicts of Interest Investors should be aware of the following potential conflicts of interest: • None of our officers and directors is required to commit their full time to our affairs and, accordingly, they may have conflicts of interest in allocating their time among various business activities. ​ • In the course of their other business activities, our officers and directors may become aware of investment and business opportunities which may be appropriate for presentation to our company as well as the other entities with which they are affiliated. Our officers and directors may have conflicts of interest in determining to which entity a particular business opportunity should be presented. ​ • Our officers and directors may in the future become affiliated with entities, including other blank check companies, engaged in business activities similar to those intended to be conducted by our company. ​ • We may engage in our initial business combination with one or more target businesses that have relationships with entities that may be affiliated with our officers, directors or existing holders, which may raise potential conflicts of interest. ​ • Unless we consummate our initial business combination, our officers, directors and other insiders will not receive reimbursement for any out-of-pocket expenses incurred by them to the extent that such expenses exceed the amount of available proceeds not deposited in the trust account. ​ • Our key personnel may negotiate employment or consulting agreements with a target business in connection with a particular business combination. These agreements may provide for them to receive compensation following our initial business combination and as a result, may cause them to have conflicts of interest in determining whether a particular business combination is the most advantageous. ​ • The founder shares beneficially owned by our officers and directors will be released from the lock-up arrangement only if our initial business combination is successfully completed. Additionally, if we are unable to complete an initial business combination within the required time frame, our officers and directors will not be entitled to receive any amounts held in the trust account with respect to any of their founder shares or private shares. Furthermore, 5:01 Acquisition LLC has agreed that the private shares will not be sold or transferred by it until after we have completed our initial business combination. For the foregoing reasons, our board may have a conflict of interest in determining whether a particular target business is an appropriate business with which to effect our initial business combination. ​ In general, officers and directors of a corporation incorporated under the laws of the State of Delaware are required to present business opportunities to a corporation if: • the corporation could financially undertake the opportunity; ​ • the opportunity is within the corporation’s line of business; and ​ • it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation. ​ 92 TABLE OF CONTENTS Accordingly, as a result of multiple business affiliations, our officers and directors may have similar legal obligations relating to presenting business opportunities meeting the above-listed criteria to multiple entities. Furthermore, our amended and restated certificate of incorporation provides that the doctrine of corporate opportunity will not apply with respect to any of our officers or directors in circumstances where the application of the doctrine would conflict with any fiduciary duties or contractual obligations they may have. In order to minimize potential conflicts of interest which may arise from multiple affiliations, our officers and directors (other than our independent directors) have agreed to present to us for our consideration, prior to presentation to any other person or entity, any suitable opportunity to acquire a target business, until the earlier of: (1) our consummation of an initial business combination and (2) 24 months from the date of this prospectus. This agreement is, however, subject to any pre-existing fiduciary and contractual obligations such officer or director may from time to time have to another entity. Accordingly, if any of them becomes aware of a business combination opportunity which is suitable for an entity to which he or she has pre-existing fiduciary or contractual obligations, he or she will honor his or her fiduciary or contractual obligations to present such business combination opportunity to such entity, and only present it to us if such entity rejects the opportunity. We do not believe, however, that the pre-existing fiduciary duties or contractual obligations of our officers and directors will materially undermine our ability to complete our business combination.

Holder Stats

1 0
% of Shares Held by All Insider 0.00%
% of Shares Held by Institutions 89.87%
% of Float Held by Institutions 89.87%
Number of Institutions Holding Shares 40

Mutual Fund Holders

Holder Shares Date Reported Value % Out
Investment Managers Ser Tr-Vivaldi Merger Arbitrage Fd 25380 2021-03-30 253546 0.29
Putnam PanAgora Market Neutral Fd 2563 2021-02-27 27193 0.03

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-16 Millennium Management LLC 286,121 $2,810,000 0.0% +3.7% 3.319%
2021-11-16 Citadel Advisors LLC 395,564 $3,880,000 0.0% -0.6% 4.588%
2021-11-15 Berkley W R Corp 52,868 $520,000 0.0% 0 0.613%
2021-11-15 Morgan Stanley 4,800 $47,000 0.0% +380.0% 0.056%
2021-11-15 Athanor Capital LP 89,785 $880,000 0.1% -3.5% 1.041%
2021-11-12 Sculptor Capital LP 398,972 $3,920,000 0.0% +35.1% 4.628%
2021-11-12 Wolverine Asset Management LLC 15,237 $150,000 0.0% +58.3% 0.177%
2021-11-10 Goldman Sachs Group Inc. 412,759 $4,050,000 0.0% +3.2% 4.788%
2021-08-17 Millennium Management LLC 275,999 $2,750,000 0.0% +14.3% 3.201%
2021-08-17 Boothbay Fund Management LLC 28,537 $290,000 0.0% +24.3% 0.331%
2021-08-17 Caas Capital Management LP 28,800 $290,000 0.0% -4.0% 0.334%
2021-08-17 Citadel Advisors LLC 397,813 $3,970,000 0.0% +0.7% 4.614%
2021-08-16 Vivaldi Asset Management LLC 33,702 $340,000 0.1% +32.8% 0.391%
2021-08-13 Glazer Capital LLC 494,846 $4,930,000 0.1% -2.4% 5.740%
2021-05-18 Millennium Management LLC 241,452 $2,410,000 0.0% -3.0% 2.801%
2021-05-18 Citadel Advisors LLC 394,853 $3,900,000 0.0% +18.3% 4.580%
2021-05-18 Radcliffe Capital Management L.P. 199,611 $1,990,000 0.1% +6.0% 2.315%
2021-05-17 Vivaldi Asset Management LLC 25,380 $250,000 0.0% 0 0.294%
2021-05-17 Schonfeld Strategic Advisors LLC 11,056 $110,000 0.0% -97.4% 0.128%
2021-05-17 Shaolin Capital Management LLC 20,167 $200,000 0.0% -79.8% 0.234%
2021-05-17 Vivaldi Capital Management LLC 10,720 $110,000 0.0% 0 0.124%
2021-05-17 HBK Investments L P 162,100 $1,620,000 0.0% -19.0% 1.880%
2021-05-17 Centiva Capital LP 30,000 $300,000 0.0% -48.3% 0.348%
2021-05-17 Goldman Sachs Group Inc. 400,000 $3,980,000 0.0% 0 4.640%
2021-05-14 Sculptor Capital LP 295,372 $2,950,000 0.0% -1.5% 3.426%
2021-05-14 Nantahala Capital Management LLC 186,650 $1,860,000 0.1% 0 2.165%
2021-05-14 Cowen Investment Management LLC 70,000 $700,000 0.3% -30.0% 0.812%
2021-05-14 Weiss Asset Management LP 24,966 $250,000 0.0% -88.1% 0.290%
2021-05-13 Wolverine Asset Management LLC 7,493 $74,000 0.0% -39.1% 0.087%
2021-05-12 Pura Vida Investments LLC 219,136 $2,180,000 0.1% +0.5% 2.542%
2021-05-12 Panagora Asset Management Inc. 7,506 $75,000 0.0% -25.5% 0.087%
2021-02-24 Alyeska Investment Group L.P. 600,000 $6,100,000 0.1% 0 6.960%
2021-02-19 Sculptor Capital LP 300,000 $3,050,000 0.0% 0 3.480%
2021-02-16 Alyeska Investment Group L.P. 600,000 $6,100,000 0.1% 0 6.960%
2021-02-16 Pura Vida Investments LLC 218,000 $2,220,000 0.1% 0 2.529%
2021-02-16 Radcliffe Capital Management L.P. 188,300 $1,920,000 0.1% 0 2.184%
2021-02-16 DeepCurrents Investment Group LLC 17,084 $170,000 0.0% 0 0.198%
2021-02-16 Glazer Capital LLC 492,008 $5,000,000 0.2% 0 5.707%
2021-02-12 Caas Capital Management LP 30,000 $310,000 0.0% 0 0.348%
2021-02-12 Crestline Management LP 18,700 $190,000 0.0% 0 0.217%
2021-02-12 Cowen Investment Management LLC 100,000 $1,020,000 0.5% 0 1.160%
2021-02-12 AWM Investment Company Inc. 100,000 $1,020,000 0.1% 0 1.160%
2021-02-11 Monashee Investment Management LLC 200,000 $2,029,999 0.3% 0 2.320%
2021-02-10 Panagora Asset Management Inc. 10,069 $100,000 0.0% 0 0.117%

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q 10-Q 2021-11-10 https://www.sec.gov/Archives/edgar/data/1823465/000110465921136948/fvam-20210930x10q.htm
DEFA14A DEFA14A 2021-10-29 https://www.sec.gov/Archives/edgar/data/1823465/000114036121035957/edge20000817x2_defa14a.htm
DEF 14A DEF 14A 2021-10-29 https://www.sec.gov/Archives/edgar/data/1823465/000114036121035953/edge20000817x1_def14a.htm
SC 13G FORM SC 13G 2021-10-15 https://www.sec.gov/Archives/edgar/data/1823465/000106299321009580/formsc13g.htm
10-Q FORM 10-Q 2021-08-11 https://www.sec.gov/Archives/edgar/data/1823465/000110465921103506/fvam-20210630x10q.htm
10-Q FORM 10-Q 2021-05-07 https://www.sec.gov/Archives/edgar/data/1823465/000110465921063214/tm2112453d1_10q.htm
10-K 10-K 2021-03-17 https://www.sec.gov/Archives/edgar/data/1823465/000110465921037704/tm218857-1_10k.htm
SC 13G THE SCHEDULE 13G 2021-03-05 https://www.sec.gov/Archives/edgar/data/1823465/000092189521000645/sc13g07422fvam_03042021.htm
SC 13G SC 13G 2021-02-16 https://www.sec.gov/Archives/edgar/data/1823465/000110465921024222/tm216584d13_sc13g.htm
SC 13G SC 13G 2021-02-16 https://www.sec.gov/Archives/edgar/data/1823465/000110465921023841/a21-6693_5sc13g.htm
SC 13G SCHEDULE 13G HOLDINGS REPORT 2021-02-16 https://www.sec.gov/Archives/edgar/data/1823465/000117266121000545/alyeska-fvam123120.htm
SC 13G 2021-02-16 https://www.sec.gov/Archives/edgar/data/1823465/000107680921000081/fvam20201231.htm
4 FORM 4 SUBMISSION 2020-12-01 https://www.sec.gov/Archives/edgar/data/1823465/000120919120060949/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-12-01 https://www.sec.gov/Archives/edgar/data/1823465/000120919120060946/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-12-01 https://www.sec.gov/Archives/edgar/data/1823465/000120919120060944/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-11-18 https://www.sec.gov/Archives/edgar/data/1823465/000120919120059118/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-11-18 https://www.sec.gov/Archives/edgar/data/1823465/000120919120059108/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-11-18 https://www.sec.gov/Archives/edgar/data/1823465/000120919120059093/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-11-18 https://www.sec.gov/Archives/edgar/data/1823465/000120919120059088/xslF345X03/doc4.xml
3 FORM 3 SUBMISSION 2020-11-18 https://www.sec.gov/Archives/edgar/data/1823465/000120919120059082/xslF345X02/doc3.xml
10-Q FORM 10-Q 2020-11-18 https://www.sec.gov/Archives/edgar/data/1823465/000110465920126873/tm2036192d1_10q.htm
8-K FORM 8-K 2020-11-18 https://www.sec.gov/Archives/edgar/data/1823465/000110465920126867/tm2036192d2_8k.htm
4 FORM 4 SUBMISSION 2020-11-12 https://www.sec.gov/Archives/edgar/data/1823465/000120919120058086/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-11-12 https://www.sec.gov/Archives/edgar/data/1823465/000120919120058079/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-11-12 https://www.sec.gov/Archives/edgar/data/1823465/000120919120058073/xslF345X03/doc4.xml
SC 13G 2020-10-23 https://www.sec.gov/Archives/edgar/data/1823465/000090514820001139/efc20-787_sc13g.htm
8-K FORM 8-K 2020-10-22 https://www.sec.gov/Archives/edgar/data/1823465/000110465920117176/tm2034050d1_8k.htm
4 FORM 4 SUBMISSION 2020-10-20 https://www.sec.gov/Archives/edgar/data/1823465/000120919120055443/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-10-20 https://www.sec.gov/Archives/edgar/data/1823465/000120919120055438/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-10-20 https://www.sec.gov/Archives/edgar/data/1823465/000120919120055435/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-10-20 https://www.sec.gov/Archives/edgar/data/1823465/000120919120055433/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-10-20 https://www.sec.gov/Archives/edgar/data/1823465/000120919120055431/xslF345X03/doc4.xml
4 FORM 4 SUBMISSION 2020-10-20 https://www.sec.gov/Archives/edgar/data/1823465/000120919120055429/xslF345X03/doc4.xml
3/A FORM 3/A SUBMISSION 2020-10-20 https://www.sec.gov/Archives/edgar/data/1823465/000120919120055427/xslF345X02/doc3a.xml
8-K FORM 8-K 2020-10-16 https://www.sec.gov/Archives/edgar/data/1823465/000110465920115647/tm2030399-11_8k.htm
424B4 424B4 2020-10-14 https://www.sec.gov/Archives/edgar/data/1823465/000110465920114897/tm2030399-10_424b4.htm
EFFECT 2020-10-13 https://www.sec.gov/Archives/edgar/data/1823465/999999999520002831/xslEFFECTX01/primary_doc.xml
3 FORM 3 SUBMISSION 2020-10-13 https://www.sec.gov/Archives/edgar/data/1823465/000120919120054702/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2020-10-13 https://www.sec.gov/Archives/edgar/data/1823465/000120919120054700/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2020-10-13 https://www.sec.gov/Archives/edgar/data/1823465/000120919120054698/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2020-10-13 https://www.sec.gov/Archives/edgar/data/1823465/000120919120054696/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2020-10-13 https://www.sec.gov/Archives/edgar/data/1823465/000120919120054694/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2020-10-13 https://www.sec.gov/Archives/edgar/data/1823465/000120919120054692/xslF345X02/doc3.xml
8-K FORM 8-K 2020-10-13 https://www.sec.gov/Archives/edgar/data/1823465/000110465920114585/tm2030399-9_8k.htm
3 FORM 3 SUBMISSION 2020-10-13 https://www.sec.gov/Archives/edgar/data/1823465/000120919120054686/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2020-10-13 https://www.sec.gov/Archives/edgar/data/1823465/000120919120054682/xslF345X02/doc3.xml
3 FORM 3 SUBMISSION 2020-10-13 https://www.sec.gov/Archives/edgar/data/1823465/000120919120054679/xslF345X02/doc3.xml
CERT 2020-10-09 https://www.sec.gov/Archives/edgar/data/1823465/000135445720000574/8A_Cert_FVAM.pdf
8-A12B FORM 8-A12B 2020-10-08 https://www.sec.gov/Archives/edgar/data/1823465/000110465920113466/tm2030399-6_8a12.htm
S-1/A S-1/A 2020-10-08 https://www.sec.gov/Archives/edgar/data/1823465/000110465920113307/tm2030399-4_s1a.htm
S-1 S-1 2020-09-25 https://www.sec.gov/Archives/edgar/data/1823465/000110465920108690/tm2030399-2_s1.htm
DRS 2020-09-10 https://www.sec.gov/Archives/edgar/data/1823465/000110465920103955/filename1.htm